Sat, Sep 20, 2014, 7:36 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Staples, Inc. Message Board

gswkool 52 posts  |  Last Activity: Sep 15, 2014 7:48 PM Member since: Jan 2, 2012
  • recommended below $11. Continue to recommend under $11 & change. The reorganization is ongoing but it appears the stock bottomed under $11. They are making right moves -closing non-performing stores, reducing store size while maintaining most of their revenues. They are a popular internet site and are adding new online categories. Some will be successful and gain traction. Others they will discard. Ultimately, I think they will survive and continue to generate good cash flow. I could be wrong, but I don't put them in same camp as radio shack. One other thing to consider - the big shippers {UPS/FEX-Ex} have switched to dimensional weight pricing. This gives some pricing advantage back to retailers with box presence for some of their goods...GLTA

  • Reply to

    More delays for generic Copaxone

    by cmhe Jul 3, 2014 3:29 PM
    gswkool gswkool Jul 4, 2014 10:53 AM Flag

    Hilarious - a company that makes its living on generics trying to fight against competition for one of its own drugs - what it will get is a taste of its own medicine, so to speak.....a citizens petition -what's next? how bout a bunch of naked ladies standing in front of the FDA with signs saying "naked female genetalia against generic copaxone".....

  • interesting article. "Using a miniature model of the human intestine, only a few millimeters in size and made from stem cells, the scientists deactivated a gene in the cells tied to metabolic regulation called FOXO1. Once disabled, the cells began producing insulin. " possibly up ALNYs alley?

    "The method, described today in the journal Nature Communications, raises the possibility of replacing insulin-making pancreatic beta cells lost in diabetics by using a drug to retrain patients’ existing cells. While progress has been made in generating beta cells from stem cells, the method hasn’t yet produced ones with all the needed functions, said Domenico Accili, the study’s lead author. Plus, such cells would require transplantation. "

  • gswkool by gswkool Jun 30, 2014 9:44 PM Flag

    I looked at Alimera's market expansion plans for Lluvien and did not see anything for Asia. Are there future plans for expansion into Asia? Is there a market there for such a product? I would expect so.....?

  • happy with the upward stock price movement and the nice dividend.....GLTA

  • Reply to

    Pretty Soon IT Will Be 4 Months Since Complete Hold!!

    by mruyog Jun 27, 2014 10:15 AM
    gswkool gswkool Jun 28, 2014 11:19 AM Flag

    gotta question mgmt's competence vs an outfit like Mayo clinic. Mayo got their hold lifted. How long for GERN to get their hold removed? I am concerned about their competnece to do so as a shareholder. I'm giving it 6 months -if no news by then will re-evaluate my position....GLTA

  • gswkool by gswkool Jun 25, 2014 8:50 AM Flag

    symboll for Aerie Pharmaceuticals -check out the news today......

  • ..at this point it appears to be getting close to bottom, if not there already. The one thing I would worry about here is the dividend. As a percentage of free cash flow they are paying out a high amount. I don't know that they would cut it. I have to think -if they did, would I want to be holding the stock? Not as an income play. As a turnaround play, -I would consider buying it after the cut. I don't put Staples in same category as Radio Shack based on their recent moves to diversify their income streams by diversifying their product offerings. Purchasing is a gamble, but it could be one worth taking at this point - dollar cost averaging purchases over a period of time {say a year} would be prudent....GLTA

  • gswkool gswkool Jun 22, 2014 11:04 AM Flag

    it's good to diversify. The STEM data look good. Waiting on ACTC data. ACTC has and had its share of problems. I disregarded past and bought the potential with a recent buy. Also own shares in ATHX, MBLTY, OSIR, NBS, & PSTI. That's it in stem cell arena -hope I have my bases covered....anyone else want to share?
    ......GLTA

  • Reply to

    Zacks finally got one right {imo}

    by gswkool Jun 20, 2014 10:50 AM
    gswkool gswkool Jun 22, 2014 10:57 AM Flag

    "So investors may definitely want to consider this Zacks Rank #3 (Hold) stock to profit in the near future" - i believe that's the part they got right. Why didn't they rate it a "buy" at this price? I have no clue. And, yes, that's inconsistent. I suppose they will rate it a buy "after" the stock doubles on good news. Anyhow, I'm not waiting - I'm buying.....GLTA

  • Reply to

    NASDAQ up 25 points

    by emkrgod Jun 18, 2014 10:07 PM
    gswkool gswkool Jun 22, 2014 10:38 AM Flag

    sorry for your disappointment -i am holding my shares and believe it's a 2nd half of the year stock - it does not burn much cash so ok to be patient in my estimate. I have lost money if i sell this one now. ....unfortunately.....GLTA

  • doesn't mean we will get good results here, but certainly bodes well. STEM is still cheap and does not have a lot of the issues ACTC has {or had to clean up}. I now own both, as well as shares in OSIR, MBLTY, PSTI, NBS & ATHX -it's smart to diversify in stem cell area -there will be winners and losers there, -it can be difficult to tell who - the wins may be huge, though -multi-$billion market cap possibilities...GLTA

SPLS
13.05+0.01(+0.08%)Sep 19 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.